Takeshi Sugio

Takeshi Sugio

Auto-generated profile, based on publicly available information

Takeshi Sugio

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in New England Journal of Medicine
Verified
Journal Article
Open access
MHMark P. Hamilton
Mark P. Hamilton
TSTakeshi Sugio
Takeshi Sugio
TNTroy Noordenbos
Troy Noordenbos
SSShuyu Shi
Shuyu Shi
PBPhilip L. Bulterys
Philip L. Bulterys
DMDavid B. Miklos
David B. Miklos
The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy, especially the risk of T-cell neoplasms related to viral vector integration, is an emerging concern. We reviewed our clinical experience with adoptive cellular CAR T-cell therapy at our institution since 2016 and ascertained the occurrence of second tumors. In one case of secondary T-cell lymphoma, a broad array of molecular, genetic, and cellular techniques were used to interrogate the tumor, the CAR T cells, and the normal hematopoietic cells in the patient. A total of 724 patients who had received T-cell therapies at our center were included in the study. A lethal T-cell lymphoma was identified in a patient who had received axicabtagene ciloleucel therapy for diffuse large B-cell lymphoma, and both lymphomas were deeply profiled. Each lymphoma had molecularly distinct immunophenotypes and genomic profiles, but both were positive for Epstein-Barr virus and were associated with DNMT3A and TET2 mutant clonal hematopoiesis. No evidence of oncogenic retroviral integration was found with the use of multiple techniques. Our results highlight the rarity of second tumors and provide a framework for defining clonal relationships and viral vector monitoring. (Funded by the National Cancer Institute and others.).

22 June 2017 in Blood
Verified
Journal Article
Closed access
PDF file
KMKohta Miyawaki
Kohta Miyawaki
HIHiromi Iwasaki
Hiromi Iwasaki
TJTakashi Jiromaru
Takashi Jiromaru
HKHirotake Kusumoto
Hirotake Kusumoto
AYAyano Yurino
Ayano Yurino
KAKoichi Akashi
Koichi Akashi
The developmental pathway for human megakaryocytes remains unclear, and the definition of pure unipotent megakaryocyte progenitor is still controversial. Using single-cell transcriptome analysis, we have identified a cluster of cells within immature hematopoietic stem- and progenitor-cell populations that specifically expresses genes related to the megakaryocyte lineage. We used CD41 as a positive marker to identify these cells within the CD34+CD38+IL-3RαdimCD45RA− common myeloid progenitor (CMP) population. These cells lacked erythroid and granulocyte-macrophage potential but exhibited robust differentiation into the megakaryocyte lineage at a high frequency, both in vivo and in vitro. The efficiency and expansion potential of these cells exceeded those of conventional bipotent megakaryocyte/erythrocyte progenitors. Accordingly, the CD41+ CMP was defined as a unipotent megakaryocyte progenitor (MegP) that is likely to represent the major pathway for human megakaryopoiesis, independent of canonical megakaryocyte-erythroid lineage bifurcation. In the bone marrow of patients with essential thrombocythemia, the MegP population was significantly expanded in the context of a high burden of Janus kinase 2 mutations. Thus, the prospectively isolatable and functionally homogeneous human MegP will be useful for the elucidation of the mechanisms underlying normal and malignant human hematopoiesis. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points A prospectively isolatable and functionally homogeneous human megakaryocyte progenitor population resides in CMP fraction of adult bone marrow. This newly identified unipotent megakaryocyte progenitor significantly contributes to normal and malignant megakaryopoiesis.

1 September 2016 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
TSTakeshi Sugio
Takeshi Sugio
KKKoji Kato
Koji Kato
TATakatoshi Aoki
Takatoshi Aoki
TOTakanori Ohta
Takanori Ohta
NSNoriyuki Saito
Noriyuki Saito
KAKoichi Akashi
Koichi Akashi
Mogamulizumab (MOG), a humanized anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, has recently played an important role in the treatment of adult T cell leukemia/lymphoma (ATLL). Because CCR4 is expressed on normal regulatory T cells as well as on ATLL cells, MOG may accelerate graft-versus-host disease (GVHD) by eradicating regulatory T cells in patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, there is limited information about its safety and efficacy in patients treated with MOG before allo-HSCT. In the present study, 25 patients with ATLL were treated with MOG before allo-HSCT, after which 18 patients (72%) achieved remission. The overall survival and progression-free survival at 1 year post-transplantation were 20.2% (95% CI, 6.0% to 40.3%) and 15.0% (95% CI, 4.3% to 32.0%), respectively. The cumulative incidence of acute GVHD was 64.0% (95% CI, 40.7% to 80.1%) for grade II-IV and 34.7% (95% CI, 15.8% to 54.4%) for grade III-IV. The cumulative incidence of transplantation-related mortality (TRM) was 49.0% (95% CI, 27.0% to 67.8%). Six of 7 patients with acute GVHD grade III-IV died from GVHD, which was the leading cause of death. In particular, a shorter interval from the last administration of MOG to allo-HSCT was associated with more severe GVHD. MOG use before allo-HSCT may decrease the ATLL burden; however, it is associated with an increase in TRM due to severe GVHD. Because MOG is a potent anti-ATLL agent, new treatment protocols should be developed to integrate MOG at suitable doses and timing of administration to minimize unwanted GVHD development.

7 September 2018 in Blood Advances
Verified
Journal Article
Open access
PDF file
TSTakeshi Sugio
Takeshi Sugio
KMKohta Miyawaki
Kohta Miyawaki
KKKoji Kato
Koji Kato
KSKensuke Sasaki
Kensuke Sasaki
KYKyohei Yamada
Kyohei Yamada
KAKoichi Akashi
Koichi Akashi
Key Points: Microenvironmental immune cell signatures stratify PTCL-NOS patients into clinically meaningful disease subtypes. Immune-checkpoint inhibitors represent potential therapeutic options for a PTCL-NOS patient subgroup.

14 July 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
YKYoshikane Kikushige
Yoshikane Kikushige
TMToshihiro Miyamoto
Toshihiro Miyamoto
YKYu Kochi
Yu Kochi
YSYuichiro Semba
Yuichiro Semba
MOMaki Ohishi
Maki Ohishi
KAKoichi Akashi
Koichi Akashi
Cancer-specific metabolic activities play a crucial role in the pathogenesis of human malignancies. To investigate human acute leukemia–specific metabolic properties, we comprehensively measured the cellular metabolites within the CD34+ fraction of normal hematopoietic stem progenitor cells (HSPCs), primary human acute myelogenous leukemia (AML), and acute lymphoblastic leukemia (ALL) cells. Here, we show that human leukemia cells are addicted to the branched-chain amino acid (BCAA) metabolism to maintain their stemness, irrespective of myeloid or lymphoid types. Human primary acute leukemias had BCAA transporters for BCAA uptake, cellular BCAA, α-ketoglutarate (α-KG), and cytoplasmic BCAA transaminase-1 (BCAT1) at significantly higher levels than control HSPCs. Isotope-tracing experiments showed that in primary leukemia cells, BCAT1 actively catabolizes BCAA using α-KG into branched-chain α-ketoacids, whose metabolic processes provide leukemia cells with critical substrates for the trichloroacetic acid cycle and the synthesis of nonessential amino acids, both of which reproduce α-KG to maintain its cellular level. In xenogeneic transplantation experiments, deprivation of BCAA from daily diet strongly inhibited expansion, engraftment and self-renewal of human acute leukemia cells. Inhibition of BCAA catabolism in primary AML or ALL cells specifically inactivates the function of the polycomb repressive complex 2, an epigenetic regulator for stem cell signatures, by inhibiting the transcription of PRC components, such as zeste homolog 2 and embryonic ectoderm development. Accordingly, BCAA catabolism plays an important role in the maintenance of stemness in primary human AML and ALL, and molecules related to the BCAA metabolism pathway should be critical targets for acute leukemia treatment.

11 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
JSJoji Shimono
Joji Shimono
HMHiroaki Miyoshi
Hiroaki Miyoshi
TKTakeharu Kato
Takeharu Kato
TSTakeshi Sugio
Takeshi Sugio
KMKohta Miyawaki
Kohta Miyawaki
KOKoichi Ohshima
Koichi Ohshima
Hepatitis C virus infection is an independent prognostic factor in follicular lymphoma Hepatitis C virus infection is an independent prognostic factor in follicular lymphoma